Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast

Overview

Journal Geburtshilfe Frauenheilkd

Specialty Gynecology & Obstetrics

Date 2017 Aug 1

PMID 28757653

Citations 55

Authors

Aju Mathew

Padma S Rajagopal

Vipin Villgran

Gurprataap S Sandhu

Rachel C Jankowitz

Mini Jacob

Margaret Rosenzweig

Steffi Oesterreich

Adam Brufsky

Affiliations

Soon will be listed here.

Abstract

Background: Invasive lobular carcinoma (ILC) comprises around 10 - 15% of invasive breast cancers. Few prior studies have demonstrated a unique pattern of metastases between ILC and the more common invasive ductal carcinoma (IDC). To our knowledge, such data is limited to first sites of distant recurrence. We aimed to perform a comparison of the metastatic pattern of ILC and IDC at first distant recurrence as well as over the entire course of metastatic disease.

Methods: We used a prospectively collated database of patients with metastatic breast cancer. Breast cancer recurrence or metastases were classified into various sites and a descriptive analysis was performed.

Results: Among 761 patients, 88 (11.6%) were diagnosed with ILC and 673 (88.4%) with IDC. Patients with ILC showed more frequent metastases to the bone (56.8 vs. 37.7%, p = 0.001) and gastrointestinal (GI) tract (5.7 vs. 0.3%, p < 0.001) as first site of distant recurrence, and less to organs such as lung (5.7 vs. 24.2%, p < 0.001) and liver (4.6 vs. 11.4%, p = 0.049). Over the entire course of metastatic disease, more patients with ILC had ovarian (5.7 vs. 2.1%, p = 0.042) and GI tract metastases (8.0 vs. 0.6%, p < 0.001), also demonstrating reduced tendency to metastasize to the liver (20.5 vs. 49.0%, p < 0.001) and lung (23.9 vs. 51.9%, p < 0.001). All associations but bone held after sensitivity analysis on hormonal status. Although patients presenting with ILC were noted to have more advanced stage at presentation, recurrence-free survival in these patients was increased (4.8 years vs. 3.2 years, p = 0.017). However, overall survival was not (2.5 vs. 2.0 years, p = 0.75).

Conclusion: After accounting for hormone receptor status, patients with IDC had greater lung/pleura and liver involvement, while patients with ILC had a greater propensity to develop ovarian and GI metastases both at first site and overall. Clinicians can use this information to provide more directed screening for metastases; it also adds to the argument that these two variants of breast cancer should be managed as unique diseases.

Citing Articles

Long-Term Survival of Metachronous Isolated Adrenal Metastasis in Luminal Breast Cancer: A Case Report and Literature Review.

Verboven G, Huizing M, Weijer M, Ysebaert D, Ramadhan A, Wyngaert T Cureus. 2025; 17(1):e78142.

PMID: 40018471 PMC: 11867634. DOI: 10.7759/cureus.78142.

E-Cadherin-Mediated Cell-Cell Adhesion and Invasive Lobular Breast Cancer.

Bullock E, Brunton V Adv Exp Med Biol. 2025; 1464():259-275.

PMID: 39821030 DOI: 10.1007/978-3-031-70875-6_14.

Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast.

Sottnik J, Shackleford M, Nesiba C, Richer A, Swartz J, Rowland C bioRxiv. 2024; .

PMID: 39677775 PMC: 11642799. DOI: 10.1101/2023.10.29.564555.

Ileocecal Valve Metastasis Inducing Cecal Volvulus in a Patient With Lobular Breast Cancer: A Rare Cause of Bowel Obstruction.

Avila L, Branco T, Leandro H, Silva R, Mendes R, Coelho F Cureus. 2024; 16(11):e73345.

PMID: 39655098 PMC: 11627466. DOI: 10.7759/cureus.73345.

Mutations Matter: Unravelling the Genetic Blueprint of Invasive Lobular Carcinoma for Progression Insights and Treatment Strategies.

Kontogiannis A, Karaviti E, Karaviti D, Lanitis S, Gomatou G, Syrigos N Cancers (Basel). 2024; 16(22).

PMID: 39594781 PMC: 11593237. DOI: 10.3390/cancers16223826.

References

Adachi Y, Ishiguro J, Kotani H, Hisada T, Ichikawa M, Gondo N . Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer. 2016; 16:248. PMC: 4807554. DOI: 10.1186/s12885-016-2275-4. View

Le Gal M, Ollivier L, Asselain B, Meunier M, Laurent M, Vielh P . Mammographic features of 455 invasive lobular carcinomas. Radiology. 1992; 185(3):705-8. DOI: 10.1148/radiology.185.3.1438749. View

Li C, Anderson B, Daling J, Moe R . Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003; 289(11):1421-4. DOI: 10.1001/jama.289.11.1421. View

Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P . E-cadherin germline mutations in familial gastric cancer. Nature. 1998; 392(6674):402-5. DOI: 10.1038/32918. View

Inoue M, Nakagomi H, Nakada H, Furuya K, Ikegame K, Watanabe H . Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer. Breast Cancer. 2017; 24(5):667-672. DOI: 10.1007/s12282-017-0753-4. View

Korhonen T, Kuukasjarvi T, Huhtala H, Alarmo E, Holli K, Kallioniemi A . The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. Breast. 2013; 22(6):1119-24. DOI: 10.1016/j.breast.2013.06.001. View

Sawyer E, Roylance R, Petridis C, Brook M, Nowinski S, Papouli E . Genetic predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet. 2014; 10(4):e1004285. PMC: 3990493. DOI: 10.1371/journal.pgen.1004285. View

Pestalozzi B, Zahrieh D, Mallon E, Gusterson B, Price K, Gelber R . Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008; 26(18):3006-14. DOI: 10.1200/JCO.2007.14.9336. View

Li C, Daling J, Haugen K, Tang M, Porter P, Malone K . Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age. Breast Cancer Res Treat. 2014; 145(2):481-9. PMC: 4075765. DOI: 10.1007/s10549-014-2960-4. View

10.

Garcia-Fernandez A, Lain J, Chabrera C, Garcia Font M, Fraile M, Barco I . Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival. Breast J. 2015; 21(5):533-7. DOI: 10.1111/tbj.12455. View

11.

Guiu S, Wolfer A, Jacot W, Fumoleau P, Romieu G, Bonnetain F . Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?. Crit Rev Oncol Hematol. 2014; 92(3):235-57. DOI: 10.1016/j.critrevonc.2014.07.003. View

12.

Barroso-Sousa R, Metzger-Filho O . Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. Ther Adv Med Oncol. 2016; 8(4):261-6. PMC: 4952020. DOI: 10.1177/1758834016644156. View

13.

Ciriello G, Gatza M, Beck A, Wilkerson M, Rhie S, Pastore A . Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 2015; 163(2):506-19. PMC: 4603750. DOI: 10.1016/j.cell.2015.09.033. View

14.

Kuwabara Y, Yamada T, Yamazaki K, Du W, Banno K, Aoki D . Establishment of an ovarian metastasis model and possible involvement of E-cadherin down-regulation in the metastasis. Cancer Sci. 2008; 99(10):1933-9. PMC: 11158956. DOI: 10.1111/j.1349-7006.2008.00946.x. View

15.

Fournier A, Fabre A, Mesrine S, Boutron-Ruault M, Berrino F, Clavel-Chapelon F . Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008; 26(8):1260-8. PMC: 2346534. DOI: 10.1200/JCO.2007.13.4338. View

16.

Lamovec J, Bracko M . Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol. 1991; 48(1):28-33. DOI: 10.1002/jso.2930480106. View

17.

Rakha E, El-Sayed M, Powe D, Green A, Habashy H, Grainge M . Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2007; 44(1):73-83. DOI: 10.1016/j.ejca.2007.10.009. View

18.

Winchester D, Chang H, Graves T, Menck H, Bland K, WINCHESTER D . A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. J Am Coll Surg. 1998; 186(4):416-22. DOI: 10.1016/s1072-7515(98)00051-9. View

19.

Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M . Genomic Characterization of Primary Invasive Lobular Breast Cancer. J Clin Oncol. 2016; 34(16):1872-81. DOI: 10.1200/JCO.2015.64.0334. View

20.

Lau M, Klausen C, Leung P . E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression. Oncogene. 2011; 30(24):2753-66. DOI: 10.1038/onc.2011.6. View